Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crucell and Talecris in protein licensing deal

This article was originally published in Scrip

Executive Summary

Crucell is to receive up to $32.5 million for licensing its PER.6 cell line technology to Talecris Biotherapeutics.Talecris will gain an exclusive commercial licence to the technology for the development of an undisclosed and specific protein. The Dutch company will receive $2.5 million up front following the execution of the agreement and be eligible for a further $30 million in milestone payments across multiple indications. The PER.6 platform enables the large-scale manufacture of biopharmaceuticals such as recombinant proteins, including monoclonal antibodies. Talecris is being acquired by Australia'sCSL, the world's second largest manufacturer of plasma products, for $3.1 billion (ScripOnline, August 14th, 2008).

You may also be interested in...



Innovation not M&A to drive Bayer growth in LatAm

Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.

2010 Scrip 100 - Is Anvisa a friend of innovators?

A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.

Elan raises $1.5 billion

Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel